NRIX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

NR

Mkt Cap

$2.66B

Volume

2.88M

Loading chart

NR

NRIXNurix Therapeutics, Inc. Common stock

NRIX

Pay with—

Available Balance0.00

NR

Mkt Cap

$2.67B

Volume

2.88M

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass EstimatesNurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.Zacks Investment Research · Oct 12, 2026

Precigen (PGEN) Soars 6.3%: Is Further Upside Left in the Stock?Economic data shows mixed signals with softer-than-expected PCE inflation and stronger-than-expected Q2 GDP growth. Market attention is turning to Friday's employment report. Precigen shares surged 6.3% on growing investor confidence in sales of its FDA-approved drug Papzimeos for recurrent respiratory papillomatosis, with expected quarterly earnings up 181.8% year-over-year.Zacks Investment Research · Oct 1, 2026

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue EstimatesAnaptysBio (ANAB) reported a quarterly loss of $0.11 per share, beating consensus estimates of $0.46 loss, with a 76% earnings surprise. However, the company received a Zacks Rank #4 (Sell) rating due to unfavorable estimate revision trends. The Medical - Biomedical and Genetics industry ranks in the bottom 32% of sectors. Nurix Therapeutics (NRIX) is expected to report results with a projected loss of $0.56 per share but with significant revenue growth of 1665.8% year-over-year.Zacks Investment Research · Sep 21, 2026

Molecular Glues Clinical Trial Landscape: 80+ Emerging Competitors, Pipeline Dynamics, and Future Opportunities | DelveInsightThe molecular glues market is experiencing significant growth with over 80 active players developing 90+ pipeline candidates. Key companies including Revolution Medicines, Gluetacs Therapeutics, Captor Therapeutics, and others are advancing promising molecular glue degraders across oncology, immunology, and neurodegenerative diseases. Recent developments include FDA Breakthrough Therapy Designation for Daraxonrasib and multiple clinical trial initiations, positioning molecular glues as a promising therapeutic strategy for previously undruggable proteins.GlobeNewswire Inc. · Jul 23, 2026

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer MarketNurix Therapeutics announced a strategic partnership with Roche to co-develop and co-commercialize bexobrutideg, a BTK degrader for B-cell blood cancers. Nurix will receive $700 million upfront with potential milestone payments up to $2.3 billion total. The companies will share development costs (40/60 split) and equally split U.S. commercialization profits, while Roche handles international sales with royalties to Nurix. NRIX stock surged 51.23% in premarket trading.Benzinga · Jun 8, 2026

Nurix Therapeutics to Participate in Upcoming Investor ConferencesNurix Therapeutics announced that its CEO Arthur T. Sands will participate in fireside chats at the RBC Global Healthcare Conference (May 20, 2026) and Jefferies Global Healthcare Conference (June 3, 2026). The company is advancing targeted protein degradation medicines for oncology and autoimmune diseases, with clinical-stage programs including BTK degraders and CBL-B inhibitors, alongside partnerships with Sanofi, Gilead, and Pfizer.GlobeNewswire Inc. · May 13, 2026

Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026Nurix Therapeutics presented preclinical data at AACR 2026 demonstrating advances across its oncology pipeline, including pan-mutant BRAF degrader NRX-0305, CBL-B inhibitor NX-1607, and AURKA degrader NRX-4972. The data showcase the potential of targeted protein degradation therapies to overcome limitations of traditional inhibitors, with NRX-0305 showing 142% lifespan extension in resistant melanoma models and NRX-4972 achieving 60% survival in SCLC models compared to 0% for existing AURKA inhibitors.GlobeNewswire Inc. · Apr 22, 2026

Follicular Lymphoma Clinical Trial Space Intensifies with 45+ Companies in Active Development | DelveInsightThe follicular lymphoma drug development pipeline is experiencing significant growth with 45+ companies actively developing 50+ pipeline therapies. Major pharmaceutical players including AstraZeneca, Bristol-Myers Squibb, Merck Sharp & Dohme, and others are advancing promising candidates through various clinical trial phases, with approximately 5+ drugs in late-stage development. The emerging therapeutic landscape shows a shift toward targeted, oral, and patient-centric therapies with diverse mechanisms of action including protein degraders, kinase inhibitors, and immune-mediated approaches.GlobeNewswire Inc. · Apr 21, 2026

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateNurix Therapeutics reported Q1 2026 financial results with revenue of $6.3 million (down from $18.5 million YoY) and net loss of $87.2 million. The company is advancing its registrational program for bexobrutideg with Phase 2 DAYBreak CLL-201 enrollment ongoing for accelerated approval in relapsed/refractory CLL, and plans to initiate Phase 3 DAYBreak CLL-306 by mid-2026. Nurix maintains a strong cash position of $540.7 million and is expanding bexobrutideg into immunology/inflammation indications with a new tablet formulation targeting 2026 IND submission.GlobeNewswire Inc. · Apr 8, 2026

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 MillionRedmile Group increased its stake in Nurix Therapeutics by 4.4 million shares worth $63.43 million, bringing its total position to 11.31% of its assets. Despite the stock being down 6.5% over the past year, the fund's conviction in the biotech company reflects confidence in its lead BTK degrader program entering a registrational trial with strong Phase 1 data showing 83% objective response rate.The Motley Fool · Feb 22, 2026

to start trading

NR

NRIXNurix Therapeutics, Inc. Common stock

NRIX

Pay with—

Available Balance0.00

Your PositionYou don't own any NRIX yet.

Related Tickers

Earnings